Microbiotica unveils data on the mechanism of action of MB310, a clinical-stage drug candidate in development for the treatment of ulcerative colitis
Data presented at key congresses in North America and Europe
Cambridge, UK – 21 February 2025: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), has presented new data on the mechanism of action of MB310, its product in development as a treatment for ulcerative colitis (UC), at the Keystone Symposia ‘Human Microbiome: Diversity, Selection and Adaptation’ held February 18-21 in Banff, Canada and at the European Crohn’s and Colitis Organisation (ECCO) meeting held February 19-22 in Berlin.
